Tandem Diabetes Care (TNDM) announced that its t:slim X2 insulin pump with Control-IQ+ automated insulin delivery technology is now cleared for use with Eli Lilly and Company’s (LLY) Lyumjev ultra-rapid acting insulin in the United States. “This latest milestone reinforces our commitment to facilitating choice and access for people who rely on insulin therapy,” said Jordan Pinsker, MD, Chief Medical Officer at Tandem Diabetes Care. “This clearance allows people with type 1 diabetes ages 2 and above and all adults with type 2 diabetes to use Lyumjev with the t:slim X2 insulin pump, providing more flexibility for how people choose to manage their diabetes.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Leerink says removal of C-peptide requirement would benefit pump market, Tandem
- Tandem Diabetes announces publication of 2IQP study in Diabetes Care
- Tandem Diabetes Care: Strategic Initiatives and Market Challenges Justify Hold Rating
- Tandem Diabetes assumed with an Outperform at Oppenheimer
- Tandem announces Health Canada authorization for t:slim mobile application